PyridoxyL EthylDiamine (PLED)-derivatives belong to a new class of SOD mimetics with metal chelating properties

PLED molecules

Oxygen-derived free radicals

Oxygen sustains us but it also harms our cells via oxygen-derived free radicals, including ·O2 (superoxide radicals) and ·OH (hydroxyl radicals). Superoxide radicals and iron are key players in the production of ·OH. For example, in cancer treatment, myocardial ischemia-reperfusion and inflammation, radical production often exceeds the endogenous protective capability.

Knowledge about endogenous cellular protective systems has provided us with new clues to treat and prevent disease. Superoxide dismutase (SOD), discovered more than 40 years ago by James McCord and Irvine Fridovich, belong to the most powerful cellular protective systems. PledPharma looks to exploit this effect through the use of PLED-derivatives.


PyridoxyL EthylDiamine (PLED)-derivatives belong to a new class of SOD mimetics with metal chelating properties. By dismutating ·O2, PLED-derivatives protect important cellular components, e.g., NO· (nitric oxide) from forming highly toxic ONOO- (peroxynitrate). For example, peroxynitrate turns off the enzymatic activity of endogenous cellular SOD enzymes. In addition, PLED-derivatives have an extremely high Fe3+-affinity. The SOD mimetic activity in combination with high iron chelating capacity make PLED-derivatives extremely effective in arresting production of the most toxic reactive oxygen species, namely the hydroxyl radical (·OH)

Scientific rationale for using PLED derivatives as therapeutics

PLED-derivatives mimic the mitochondrial enzyme manganese superoxide dismutase (MnSOD). MnSOD protects the mammalian cell from superoxide radicals (·O2), which is produced in fairly high amounts during normal aerobic conditions – no mammalians survive without a functional MnSOD. MnSOD has the fastest turnover rate (reaction rate with its substrate) of any known enzyme (>109 M-1 s-1). SOD mimetics may have turnover rates close to that of native MnSOD.

Efficacious inactivation of superoxide is essential in preventing generation of devastating ·OH radicals and peroxynitrite. During pathological oxidative stress, the formation of superoxide radicals often exceeds the endogenous capacity for inactivation. Exogenous addition of PLED-derivatives may in such situations re-establish the protective potential. PLED-derivatives are in addition strong iron binders, and some PLED-derivatives may have catalase and glutathione reductase activities, which may further increase their antioxidant capacity.

The PLED-derivative mangafodipir has been shown to protect mice against serious side effects of several chemotherapy drugs (doxorubicin, oxaliplatin, 5-fluorouracil and paclitaxel), e.g., against the myelosuppressive effects of oxaliplatin and cardiotoxic effects of doxorubicin. The cytoprotective effects are obtained without interfering negatively with the anticancer effect of these drugs. Contrary, mangafodipir potentiates the anticancer effect of several cytotoxic/cytostatic drugs. Mangafodipir has been tested in one colorectal cancer patient going through palliative treatment with a combination of folinate, 5-fluorouracil and oxaliplatin (“Nordic FLOX”, similar to the FOLFOX regimen). The preclinical data and the results from this single patient were promising enough to start a clinical feasibility study in colorectal cancer patients in Sweden (MANFOL I), which has been completed.

Mangafodipir has also been shown to protect mice against acetaminophen (paracetamol)-induced acute liver failure in mice (ALF). ALF is characterized by massive hepatocyte cell death, a condition caused by glutathione depletion, oxygen-derived free radicals and mitochondrial damage.



Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com